Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Cirrhosis
  Free Subscription

Articles published in
PLoS One
    January 2026
  1. BAGULEY E, Knaub M, VanDyke J, Hirschfield G, et al
    Evaluating the clinical care, quality of life and overall experiences of patients with primary biliary cholangitis (PBC) during the pandemic: A Canadian mixed-methods study.
    PLoS One. 2026;21:e0340475.
    >> Share

  2. PINJAROEN N, Pan-Ngum W, Poovorawan K, Wastlund D, et al
    Economic evaluation of biomarker-based surveillance for Hepatocellular Carcinoma in Thai patients with Compensated Liver Cirrhosis.
    PLoS One. 2026;21:e0337913.
    >> Share

  3. SU T, Lai S, Chen H
    Intestinal decontamination with rifaximin attenuates LSEC dysfunction and liver fibrosis in mice.
    PLoS One. 2026;21:e0340664.
    >> Share

  4. TOH C, Sanit K, Sripongpun P, Chamroonkul N, et al
    Impact of cardiometabolic risk factors on hepatocellular carcinoma incidence in patients with chronic hepatitis B: A retrospective cohort study.
    PLoS One. 2026;21:e0341366.
    >> Share

  5. KITAGATAYA T, Krishnan A, Olson KE, Gutierrez F, et al
    Genetic ablation of interleukin-17A augments fibrosis in a mouse model of cholestatic liver injury.
    PLoS One. 2026;21:e0342251.
    >> Share

  6. CHEN R, Sun Y, Tai W
    A multifaceted analysis of OTUD5 integrated MAVS in innate immunity of Primary Biliary Cholangitis.
    PLoS One. 2026;21:e0342306.
    >> Share

  7. METTANANDA C, Ranawaka C, Egodage T, Dantanarayana C, et al
    Adoption and validation of the European Association for the Study of the Liver algorithm for the noninvasive diagnosis of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease in low-resource South Asian settings.
    PLoS One. 2026;21:e0341364.
    >> Share

  8. DOGAY US G, Innocenti F, Koc OM, Yumuk VD, et al
    Prevalence of MASLD and fibrosis in Turkey: Results from a multicenter study of at-risk populations.
    PLoS One. 2026;21:e0341214.
    >> Share

  9. XI J, Wang S, Chen J, Law JCS, et al
    Exploration and discovery of treatment targets for primary biliary cholangitis based on plasma and cerebrospinal fluid proteomics: A multicenter mendelian randomization study.
    PLoS One. 2026;21:e0340166.
    >> Share

  10. TANVIR L, Afzal K, Abbas A, Amjad A, et al
    Integrating phytochemical analysis and experimental validation of Ziziphus jujuba seed powder and oil to ameliorate CCl4-induced liver fibrosis in sprague dawley rats.
    PLoS One. 2026;21:e0343428.
    >> Share

  11. ZHANG S, Liu R, Li Z, Pan T, et al
    Predicting short-term mortality in severe cirrhosis: An interpretable machine learning model integrating routine clinical indicators.
    PLoS One. 2026;21:e0328952.
    >> Share

  12. IBI Y, Omori T
    Cure rate estimation with insufficient follow-up: A median-based bootstrap correction approach.
    PLoS One. 2026;21:e0344669.
    >> Share

  13. DESALEGN MM, Fisseha H, Altaye MG, Berhane KA, et al
    Prevalence and associated factors of non-variceal upper gastrointestinal bleeding among cirrhotic patients with upper gastrointestinal bleeding on follow-up at a Tertiary Hospital in Ethiopia.
    PLoS One. 2026;21:e0343977.
    >> Share

  14. LEI Y, Ma X, Jin X, He Y, et al
    Huanggan decoction ameliorates cholestatic hepatic fibrosis in rats via TGF-beta1/Smad3 signaling pathway.
    PLoS One. 2026;21:e0344168.
    >> Share

  15. ZHANG J, Feng L
    Analysis of 6-week mortality and influencing factors in patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding.
    PLoS One. 2026;21:e0345079.
    >> Share

  16. KOSITAMONGKOL C, Tantiyavarong P, Ratanatawan A, Sripongpun P, et al
    Cost-utility and budget impact analyses of significant fibrosis detection in individuals with metabolic syndrome or obesity in Thailand.
    PLoS One. 2026;21:e0344985.
    >> Share

  17. BESTARI MB, Wijaya MP, Girawan D, Agustanti N, et al
    Unveiling the role of interleukin-13 in liver fibrosis of chronic hepatitis B patients: Development of a predictive model.
    PLoS One. 2026;21:e0344791.
    >> Share

  18. SAEKI C, Oikawa T, Kanai T, Kiryu S, et al
    Clinical usefulness of serum autotaxin levels for predicting decompensation development and prognosis in patients with compensated cirrhosis.
    PLoS One. 2026;21:e0347310.
    >> Share

  19. HUH J, Choi JH, Lee ES, Ye JC, et al
    Image quality improvement of liver ultrasound using unsupervised deep learning.
    PLoS One. 2026;21:e0348137.
    >> Share

  20. ARRAMRAK K, Witayavanitkul N, Chayanupatkul M, Wanpiyarat N, et al
    Calcitriol attenuates diethylnitrosamine-induced hepatic fibrosis in rats by reducing oxidative stress and fibrogenic mediators.
    PLoS One. 2026;21:e0347908.
    >> Share


  21. Expression of concern: Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis.
    PLoS One. 2026;21:e0348620.
    >> Share

    January 2025
  22. CELDIR MG, Wehby G, Prakash S, Tanaka T, et al
    July effect in hospitalized cirrhosis patients: A US nationwide study using difference-in-differences analysis.
    PLoS One. 2025;20:e0316445.
    >> Share

  23. KIM M, Jun BG, Shin HS, Yi JJ, et al
    Impact of high body mass index on hepatocellular carcinoma risk in chronic liver disease: A population-based prospective cohort study.
    PLoS One. 2025;20:e0316175.
    >> Share

  24. TOY M, Hutton D, Conners EE, Pham H, et al
    Cost-effectiveness of monitoring and liver cancer surveillance among patients with inactive chronic hepatitis B.
    PLoS One. 2025;20:e0313898.
    >> Share

  25. DOFFOEL M, Chaffraix F, Chahard A, Gras D, et al
    Prevalence of advanced hepatic fibrosis and individualization of associated risk factors by Bayesian analysis in MASLD patients in French cardio-metabolic health networks.
    PLoS One. 2025;20:e0316158.
    >> Share

  26. YU L, Yu P, Cao Y, Cao W, et al
    Mechanism of Radix Bupleuri and Hedysarum Multijugum Maxim drug pairs on liver fibrosis based on network pharmacology, bioinformatics and molecular dynamics simulation.
    PLoS One. 2025;20:e0318336.
    >> Share

  27. STRAJHAR P, Berzigotti A, Nilius H, Nagler M, et al
    Estimating the prevalence of adults at risk for advanced hepatic fibrosis using FIB-4 in a Swiss tertiary care hospital.
    PLoS One. 2025;20:e0317629.
    >> Share

  28. SCHLEICHER EM, Tuchscher J, Weber M, Galle PR, et al
    Impact of type 2 diabetes mellitus on results in the animal naming test in patients with and without liver cirrhosis.
    PLoS One. 2025;20:e0316490.
    >> Share

  29. MOHAMMADI M, Hasjim BJ, Balbale SN, Polineni P, et al
    Disease trajectory and competing risks of patients with cirrhosis in the US.
    PLoS One. 2025;20:e0313152.
    >> Share

  30. CHO EH, Kim JA, Park MS, Kwon MJ, et al
    Mean platelet volume as a biomarker for liver fibrosis in patients with Non-alcoholic fatty liver disease.
    PLoS One. 2025;20:e0318847.
    >> Share

  31. SKLADANY L, Zilincanova D, Zilincan M, Okapec S, et al
    Hepatic venous pressure gradient in patients with (compensated and decompensated) advanced chronic liver disease - A comparison of metabolic dysfunction-associated steatotic liver disease with alcohol-associated liver disease: A retrospective view.
    PLoS One. 2025;20:e0317287.
    >> Share

  32. TEWKESBURY DH, Scott JA, Bright-Thomas RJ, Liong S, et al
    Proof of concept pilot study to assess the utility of magnetic resonance extra-cellular volume quantification to diagnose advanced liver disease in people with Cystic Fibrosis.
    PLoS One. 2025;20:e0318085.
    >> Share


  33. Expression of Concern: Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.
    PLoS One. 2025;20:e0320610.
    >> Share

  34. GUO W, Weng T, Song Y
    Association of serum iron status with MASLD and liver fibrosis.
    PLoS One. 2025;20:e0319057.
    >> Share

  35. LI Z, Guo H, He H, Wang S, et al
    The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States.
    PLoS One. 2025;20:e0320573.
    >> Share

  36. CELDIR MG, Wehby G, Prakash S, Tanaka T, et al
    Correction: July effect in hospitalized cirrhosis patients: A US nationwide study using difference-in-differences analysis.
    PLoS One. 2025;20:e0323476.
    >> Share

  37. FICHTNER UA, Maun A, Farin-Glattacker E
    Predictors for psychosocial consequences of screening for liver diseases: A data-driven approach.
    PLoS One. 2025;20:e0319488.
    >> Share

  38. ELIAS TP, Shewaye AB, Fisseha H, Nur AM, et al
    Predictors of in-hospital mortality among cirrhotic patients in Ethiopia: A multicenter retrospective study.
    PLoS One. 2025;20:e0322532.
    >> Share

  39. HJORTH M, Forsberg A
    Predictive factors for limited health literacy among persons with cirrhosis: A Swedish explorative cross-sectional study.
    PLoS One. 2025;20:e0321780.
    >> Share

  40. ZHAO K, Hu HT, Li HL, Cheng HT, et al
    Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma.
    PLoS One. 2025;20:e0323829.
    >> Share

  41. LU H, Mao Z, Zheng M, Zhang M, et al
    Identification of hub gene for the pathogenic mechanism and diagnosis of MASLD by enhanced bioinformatics analysis and machine learning.
    PLoS One. 2025;20:e0324972.
    >> Share

  42. LEE CW, Kang ES, Jeong S, Han HW, et al
    Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study.
    PLoS One. 2025;20:e0323880.
    >> Share

  43. YOO HW, Yang CJ, Yoo JJ, Chang Y, et al
    Diagnostic performance of microvascular flow imaging for noninvasive assessment of liver fibrosis in chronic liver disease.
    PLoS One. 2025;20:e0322102.
    >> Share

  44. GRANDT J, Johansen CD, Jensen AH, Werge MP, et al
    The hepatic transcriptome is differentially regulated by a standardized meal in healthy individuals compared to patients with fatty liver disease.
    PLoS One. 2025;20:e0307345.
    >> Share

  45. BUTTLER L, Tiede A, Griemsmann M, Rieland H, et al
    Differences in the incidence of cirrhosis-associated complications between MASLD, MetALD and ALD among patients with decompensated liver cirrhosis.
    PLoS One. 2025;20:e0325673.
    >> Share

  46. HUANG S, Hu W, Fang T
    The global impact of non-alcoholic fatty liver disease (including cirrhosis) in the elderly from 1990 to 2021 and future projections of disease burden.
    PLoS One. 2025;20:e0325961.
    >> Share

  47. THEEL W, Brouwer WP, van Rossum E, Apers J, et al
    Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort.
    PLoS One. 2025;20:e0324813.
    >> Share

  48. ALBHAISI S, Robinson A, Alsaadawi R, Sabo RT, et al
    Liver-related outcomes in patients with cirrhosis: The value of clinical and laboratory data and noninvasive tests.
    PLoS One. 2025;20:e0326702.
    >> Share

  49. AHN J, Kim S, Jeong JY, Heo S, et al
    Whole genome DNA methylation patterns in tissue and cfDNA associated with fibrosis reflect the complex signature of MASLD.
    PLoS One. 2025;20:e0328207.
    >> Share

  50. DUO H, You J, Du S, Yu M, et al
    Liver cirrhosis in 2021: Global Burden of Disease study.
    PLoS One. 2025;20:e0328493.
    >> Share

  51. AHMED RF, Elgamal AM, El-Nashar HAS, Mowaad NA, et al
    Phenolic-rich extracts of Teucrium oliverianum confer protection against thioacetamide-induced liver fibrosis in rats: Insights from metabolomics, biochemical and histopathological analysis.
    PLoS One. 2025;20:e0330595.
    >> Share

  52. XU C, Wang G, Zhang M, Lv L, et al
    Albumin-corrected anion gap as a predictive marker for mortality in critically Ill cirrhosis patients: an analysis based on the MIMIC-IV database.
    PLoS One. 2025;20:e0332490.
    >> Share

  53. CHAI L, Zhou Y, Zhou N, Xiao Y, et al
    Machine learning-based prediction model for 28-day mortality in acute kidney injury patients with liver cirrhosis: A MIMIC-IV database analysis.
    PLoS One. 2025;20:e0328662.
    >> Share

  54. MULLER-KUHNLE J, Schanz M, Schricker S, Benignus C, et al
    Predicting severe renal dysfunction in alcohol-associated cirrhosis: Comparative performance of liver function scores and machine learning models.
    PLoS One. 2025;20:e0332840.
    >> Share

  55. SUTTAWONG N, Witayavanitkul N, Chayanupatkul M, Wanpiyarat N, et al
    Gardenia jasminoides fruit extract ameliorates non-alcoholic steatohepatitis with fibrosis by modulating inflammatory and fibrogenic pathways.
    PLoS One. 2025;20:e0333800.
    >> Share

  56. HOLINKA M, Frankova S, Adamcova Selcanova S, Skladany L, et al
    Genetic drivers of liver cirrhosis: The role of SERPINA1 and PNPLA3 variants in disease onset and progression.
    PLoS One. 2025;20:e0333051.
    >> Share

  57. SAN MARTIN VALENZUELA C, Gallego JJ, Urios A, Correa-Ghisays P, et al
    Motor performance as a predictor of blood levels of ammonia and inflammatory biomarkers in patients with liver cirrhosis.
    PLoS One. 2025;20:e0333029.
    >> Share

  58. MIGNOT V, Fabre O, Legrand R, Bailly S, et al
    FIB-4: A screening tool for advanced liver fibrosis in a cohort of subjects participating in a primary care weight-loss program.
    PLoS One. 2025;20:e0333490.
    >> Share

  59. SCHREINER AD, Zhang J, Gebregziabher M, Marsden J, et al
    The association of race with time to severe liver disease diagnoses.
    PLoS One. 2025;20:e0334016.
    >> Share

  60. YANG X, Wang G, Min Z, Lv L, et al
    The prognostic value of the direct bilirubin to albumin ratio in critically ill patients with cirrhosis: Insights from MIMIC-IV database.
    PLoS One. 2025;20:e0334591.
    >> Share

  61. HUANG A, Su M, Zhang S, Zhao C, et al
    Alterations in the gut microbiota of alcoholic cirrhosis patients infected with Clonorchis sinensis in the Pearl River Delta region of China.
    PLoS One. 2025;20:e0334311.
    >> Share

  62. FREY LJ, Fuchs M, Ward RC, Gebregziabher M, et al
    Use of machine learning for early prediction of short-term mortality in veterans with metabolic dysfunction-associated steatotic liver disease.
    PLoS One. 2025;20:e0334715.
    >> Share

  63. PHUONG LINH TQ, Nhan NT, Thuan LM, Phuong LT, et al
    Survey of clot waveform analysis of normal activated partial thromboplastin time in patients with cirrhosis and sepsis at Le Van Thinh hospital.
    PLoS One. 2025;20:e0334920.
    >> Share

  64. LIN J, Huang M, Shen L
    Predictive value of neutrophil to lymphocyte ratio for clinical outcomes in liver cirrhosis: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0335925.
    >> Share

  65. LIU Y, Zhang R, Sun X, Cui W, et al
    Transcriptomic and experimental evidence confirm the potential of disulfidptosis-related signature for the early diagnosis and treatment of liver cirrhosis.
    PLoS One. 2025;20:e0334459.
    >> Share

  66. MAO YY, Zhang K, Zhao DD, Cui JW, et al
    Combining transcriptomics with network pharmacology to explore the mechanism of Yiqi Huoxue decoction against liver fibrosis.
    PLoS One. 2025;20:e0337061.
    >> Share

  67. SAAD ZM, Keryakos HKH, Hassanin HA, Higazi MM, et al
    MAFLD in Egyptian non-dialysis CKD Patients: Frequency, fibrosis severity, and risk factors.
    PLoS One. 2025;20:e0336568.
    >> Share

  68. SHU X, Xiong R, He Y, Li X, et al
    The experience of demoralization syndrome in patients with decompensated cirrhosis: A qualitative research.
    PLoS One. 2025;20:e0337182.
    >> Share

  69. HORI T, Aihara KI, Kawano Y, Watanabe T, et al
    Fibrosis-4 and 3 indices are independently associated with annual hemoglobin decline in individuals with metabolic disorders: A hospital-based retrospective cohort study.
    PLoS One. 2025;20:e0338372.
    >> Share

  70. KESSINGER CW, Chen L, Huang F, Lin J, et al
    Diet-induced steatohepatitis does not cause heart failure with preserved ejection fraction in male middle-aged C57BL/6N mice.
    PLoS One. 2025;20:e0339642.
    >> Share

  71. VIET QUANG NGUYEN H, Viet Luong T, Nguyen Tran T, Nguyen Ngoc Dang H, et al
    The bilirubin-to-albumin ratio as a potential prognostic biomarker for all-cause mortality in patients with acute decompensated cirrhosis: A prospective study.
    PLoS One. 2025;20:e0337206.
    >> Share

    January 2024
  72. KOGISO T, Takayanagi K, Ishizuka T, Otsuka M, et al
    Serum level of full-length connective tissue growth factor reflects liver fibrosis stage in patients with Fontan-associated liver disease.
    PLoS One. 2024;19:e0296375.
    >> Share

  73. QIANG B, Xu Q, Pan Y, Wang J, et al
    Shear wave elastography: A noninvasive approach for assessing acute kidney injury in critically ill patients.
    PLoS One. 2024;19:e0296411.
    >> Share

  74. SATO T, Oishi K
    Time-restricted feeding has a limited effect on hepatic lipid accumulation, inflammation and fibrosis in a choline-deficient high-fat diet-induced murine NASH model.
    PLoS One. 2024;19:e0296950.
    >> Share

  75. LIU Z, Shao Y, Duan X
    Genetic link between primary biliary cholangitis and connective tissue diseases in European populations: A two-sample Mendelian randomization study.
    PLoS One. 2024;19:e0298225.
    >> Share

  76. LADNER DP, Gmeiner M, Hasjim BJ, Mazumder N, et al
    Increasing prevalence of cirrhosis among insured adults in the United States, 2012-2018.
    PLoS One. 2024;19:e0298887.
    >> Share

  77. LI YS, Xia YG, Liu YL, Jiang WR, et al
    Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study.
    PLoS One. 2024;19:e0297883.
    >> Share

  78. BAGER P, Bossen L, Gantzel R, Gronbaek H, et al
    High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trial.
    PLoS One. 2024;19:e0301354.
    >> Share

  79. AZAMAR-LLAMAS D, Arenas-Martinez JS, Olivas-Martinez A, Jimenez JV, et al
    Impact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico.
    PLoS One. 2024;19:e0301198.
    >> Share

  80. RAN S, Song L, Yang H, Yu J, et al
    Piperine alleviates nonalcoholic steatohepatitis by inhibiting NF-kappaB-mediated hepatocyte pyroptosis.
    PLoS One. 2024;19:e0301133.
    >> Share

  81. CHAVEZ-TAPIA NC, Sanchez-Jimenez BA, Vidana-Perez D, Corrales-Rosas B, et al
    Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study.
    PLoS One. 2024;19:e0290632.
    >> Share

  82. GURUN M, Brennan P, Handjiev S, Khatib A, et al
    Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.
    PLoS One. 2024;19:e0299507.
    >> Share

  83. PASTROVIC F, Novak R, Grgurevic I, Hrkac S, et al
    Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.
    PLoS One. 2024;19:e0301416.
    >> Share

  84. BENGTSSON B, Maucourant C, Sandberg JK, Bjorkstrom NK, et al
    Evaluation of mucosal-associated invariant T-cells as a potential biomarker to predict infection risk in liver cirrhosis.
    PLoS One. 2024;19:e0294695.
    >> Share

  85. PAN Z, Bayoumi A, Metwally M, George J, et al
    Exportin 4 DNA promoter methylation in liver fibrosis.
    PLoS One. 2024;19:e0302786.
    >> Share

  86. TABACU L, Swami S, Ledbetter M, Siddiqui MS, et al
    Socioeconomic status and health disparities drive differences in accelerometer-derived physical activity in fatty liver disease and significant fibrosis.
    PLoS One. 2024;19:e0301774.
    >> Share

  87. YUAN C, Li W, Liu J, Li J, et al
    Frailty and transplant-free survival of patients with liver cirrhosis: A meta-analysis.
    PLoS One. 2024;19:e0302836.
    >> Share

  88. GALIERO R, Loffredo G, Simeon V, Caturano A, et al
    Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy.
    PLoS One. 2024;19:e0296495.
    >> Share

  89. OSAWA Y, Kawai H, Nakashima K, Nakaseko Y, et al
    Sphingosine-1-phosphate promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis.
    PLoS One. 2024;19:e0303296.
    >> Share

  90. CHU YH, Pang BY, Yang M, Meng Q, et al
    The intervention of curcumin on rodent models of hepatic fibrosis: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0304176.
    >> Share

  91. TARU MG, Tefas C, Neamti L, Minciuna I, et al
    FAST and Agile-the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin.
    PLoS One. 2024;19:e0303971.
    >> Share

  92. PFISTERER N, Schwarz M, Schwarz C, Putre F, et al
    Statins, metformin, and RAS inhibitors did not reduce variceal bleeding risk and mortality in a large, real-life cohort of patients with cirrhosis.
    PLoS One. 2024;19:e0302811.
    >> Share

  93. WANG F, Gan J, Li R, Yang R, et al
    Naringin from Ganshuang granule inhibits inflammatory to relieve liver fibrosis through TGF-beta-Smad signaling pathway.
    PLoS One. 2024;19:e0304185.
    >> Share

  94. NAM DE, Park SJ, Omole S, Um E, et al
    Activated Gab1 drives hepatocyte proliferation and anti-apoptosis in liver fibrosis via potential involvement of the HGF/c-Met signaling axis.
    PLoS One. 2024;19:e0306345.
    >> Share

  95. PAUKNER M, Ladner DP, Zhao L
    Dynamic risk prediction of survival in liver cirrhosis: A comparison of landmarking approaches.
    PLoS One. 2024;19:e0306328.
    >> Share

  96. QUITETE FT, Teixeira AVS, Peixoto TC, Martins BC, et al
    Long-term exposure to polychlorinated biphenyl 126 induces liver fibrosis and upregulates miR-155 and miR-34a in C57BL/6 mice.
    PLoS One. 2024;19:e0308334.
    >> Share

  97. DU PISANIE JL, Ramakrishnan V, Patel V, Commander C, et al
    MRI paraspinous skeletal muscle enhancement: A potential imaging biomarker for assessing clinical liver cirrhosis severity.
    PLoS One. 2024;19:e0308520.
    >> Share

  98. KATSUMI T, Sato H, Murakami R, Hanatani T, et al
    Identification of microbial antigens in liver tissues involved in the pathogenesis of primary biliary cholangitis using 16S rRNA metagenome analysis.
    PLoS One. 2024;19:e0308912.
    >> Share

  99. WOOLLEY JJ, Fishman J, Parrinello CM, O'Connell T, et al
    Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017-2020.
    PLoS One. 2024;19:e0309617.
    >> Share

  100. PAIK JM, Shah D, Eberly K, Golabi P, et al
    Changes in mortality due to Chronic Liver Diseases (CLD) during the COVID-19 pandemic: Data from the United States' National Vital Statistics System.
    PLoS One. 2024;19:e0289202.
    >> Share

  101. SEPEHRINEZHAD A, Moghaddam NG, Shayan N, Sahab Negah S, et al
    Correlation of ammonia and blood laboratory parameters with hepatic encephalopathy: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0307899.
    >> Share

  102. XUE H, Liu Y, Liu Y, Li H, et al
    Myosteatosis and the clinical outcomes of patients with liver cirrhosis: A meta-analysis.
    PLoS One. 2024;19:e0310017.
    >> Share

  103. LU Y, Mohammad NS, Lee J, Aranyos AM, et al
    Berberine potentiates liver inflammation and fibrosis in the PI*Z hAAT transgenic murine model.
    PLoS One. 2024;19:e0310524.
    >> Share

  104. FORLANO R, Stanic T, Jayawardana S, Mullish BH, et al
    Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community.
    PLoS One. 2024;19:e0307500.
    >> Share

  105. OHKAWA K, Nakabori T, Mukai K, Kozumi K, et al
    Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study.
    PLoS One. 2024;19:e0311930.
    >> Share

  106. PILLING D, Martinez TC, Gomer RH
    Inhibition of CCl4-induced liver inflammation and fibrosis by a NEU3 inhibitor.
    PLoS One. 2024;19:e0308060.
    >> Share

  107. WEJNARUEMARN S, Suksawatamnuay S, Vanichanan J, Komolmit P, et al
    Association between serum endocan levels and organ failure in hospitalized patients with cirrhosis.
    PLoS One. 2024;19:e0315619.
    >> Share

  108. GUO W, Weng T, Song Y
    Association of serum selenium with MASLD and liver fibrosis: A cross-sectional study.
    PLoS One. 2024;19:e0314780.
    >> Share

    January 2023
  109. THRIFT AP, Kanwal F, Liu Y, Khaderi S, et al
    Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score.
    PLoS One. 2023;18:e0282309.
    >> Share

  110. ZHOU T, Wei H, Wang J
    Research experimental design for the construction and identification of the pGEX-BCKD-E4A recombinant point-mutant plasmid.
    PLoS One. 2023;18:e0279431.
    >> Share

  111. VOROS K, Markus B, Atzel K, Szalay F, et al
    Serum fetuin-A is decreased in cirrhotic patients with Wilson's disease.
    PLoS One. 2023;18:e0282801.
    >> Share

  112. GE C, Ma C, Cui J, Dong X, et al
    Rapamycin suppresses inflammation and increases the interaction between p65 and IkappaBalpha in rapamycin-induced fatty livers.
    PLoS One. 2023;18:e0281888.
    >> Share

  113. HJORTH M, Svanberg A, Sjoberg D, Rorsman F, et al
    Feeling safe or falling through the cracks-Patients' experiences of healthcare in cirrhosis illness: A qualitative study.
    PLoS One. 2023;18:e0283611.
    >> Share

  114. RIDDELL J, Hempenstall A, Nakata Y, Gregson S, et al
    The high burden of comorbidities in Aboriginal and Torres Strait Islander Australians living with chronic hepatitis B in Far North Queensland, Australia, and the implications for patient management.
    PLoS One. 2023;18:e0284151.
    >> Share

  115. YU L, Paski SC, Dodge J, Bambha K, et al
    Effect of dietary branched chain amino acids on liver related mortality: Results from a large cohort of North American patients with advanced HCV infection.
    PLoS One. 2023;18:e0284739.
    >> Share

  116. NIITSU Y, Komiya C, Takeuchi A, Hara K, et al
    Increased serum extracellular vesicle miR-144-3p and miR-486a-3p in a mouse model of adipose tissue regeneration promote hepatocyte proliferation by targeting Txnip.
    PLoS One. 2023;18:e0284989.
    >> Share

  117. AWASTHI A, Katiyar H, Rungta S, Deep A, et al
    Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naive non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).
    PLoS One. 2023;18:e0285725.
    >> Share

  118. DU R, Tang XY, Yang C, Gao WH, et al
    Marijuana use is inversely associated with liver steatosis detected by transient elastography in the general United States population in NHANES 2017-2018: A cross-sectional study.
    PLoS One. 2023;18:e0284859.
    >> Share

  119. LI X, Lu Y, Liang X, Zhou X, et al
    A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis.
    PLoS One. 2023;18:e0286257.
    >> Share

  120. HU J, Xie C, Xu S, Pu Q, et al
    Liver fibrosis-derived exosomal miR-106a-5p facilitates the malignancy by targeting SAMD12 and CADM2 in hepatocellular carcinoma.
    PLoS One. 2023;18:e0286017.
    >> Share

  121. HE S, Zhang Y, Tan C, Tan W, et al
    Inverted U-shaped relationships between bone mineral density and VCTE-quantified degree of hepatic steatosis in adolescents: Evidence from the NHANES.
    PLoS One. 2023;18:e0286688.
    >> Share

  122. MITROVIC N, Sabanovic M, Vujovic A, Jovanovic J, et al
    Influence of chronic liver diseases on the course and outcome of COVID-19.
    PLoS One. 2023;18:e0288350.
    >> Share

  123. BRADSHAW D, Abramowicz I, Bremner S, Verma S, et al
    Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease.
    PLoS One. 2023;18:e0288598.
    >> Share

  124. SUZUKI-KEMURIYAMA N, Abe A, Nakane S, Yuki M, et al
    Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
    PLoS One. 2023;18:e0287657.
    >> Share

  125. LIAO Z, Wang Z, Su C, Pei Y, et al
    Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0290164.
    >> Share

  126. SCHWARZ M, Schwarz C, Burghart L, Pfisterer N, et al
    Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes.
    PLoS One. 2023;18:e0290352.
    >> Share

  127. SEO HY, Lee SH, Park JY, Han E, et al
    Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver.
    PLoS One. 2023;18:e0290532.
    >> Share

  128. SCHMIDT U, Uluca B, Vokic I, Malik B, et al
    Inducible overexpression of a FAM3C/ILEI transgene has pleiotropic effects with shortened life span, liver fibrosis and anemia in mice.
    PLoS One. 2023;18:e0286256.
    >> Share

  129. YOSHIDA Y, Atsukawa M, Kondo C, Kitamura M, et al
    A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C.
    PLoS One. 2023;18:e0292019.
    >> Share

  130. BEER S, Babel J, Martin N, Blank V, et al
    Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease.
    PLoS One. 2023;18:e0286882.
    >> Share

  131. GNANAPANDITHAN K, Ghali MP
    Self-awareness of hepatitis C infection in the United States: A cross-sectional study based on the National Health Nutrition and Examination Survey.
    PLoS One. 2023;18:e0293315.
    >> Share

  132. PHAM HN, Pham L, Sato K
    Bioinformatic analysis identified novel candidate genes with the potentials for diagnostic blood testing of primary biliary cholangitis.
    PLoS One. 2023;18:e0292998.
    >> Share

  133. CHACON C, Arteaga I, Martinez-Escude A, Ruiz Rojano I, et al
    Clinical epidemiology of non-alcoholic fatty liver disease in children and adolescents. The LiverKids: Study protocol.
    PLoS One. 2023;18:e0286586.
    >> Share

  134. NAGAKAWA K, Hidaka M, Hara T, Matsushima H, et al
    Serum wisteria floribunda agglutinin-positive human Mac-2 binding protein is unsuitable as a diagnostic marker of occult hepatocellular carcinoma in end-stage liver cirrhosis.
    PLoS One. 2023;18:e0293593.
    >> Share

  135. ANTWI MB, Dumitriu G, Simon-Santamaria J, Romano JS, et al
    Liver sinusoidal endothelial cells show reduced scavenger function and downregulation of Fc gamma receptor IIb, yet maintain a preserved fenestration in the Glmpgt/gt mouse model of slowly progressing liver fibrosis.
    PLoS One. 2023;18:e0293526.
    >> Share

  136. AIN NAZIR NU, Shaukat MH, Luo R, Abbas SR, et al
    Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.
    PLoS One. 2023;18:e0287465.
    >> Share

  137. WANG B, Kaufmann B, Mogler C, Zhong S, et al
    Hepatocellular Brg1 promotes CCl4-induced liver inflammation, ECM accumulation and fibrosis in mice.
    PLoS One. 2023;18:e0294257.
    >> Share

  138. MOUNIKA N, Yadav A, Kamboj P, Banerjee SK, et al
    Circulatory bone morphogenetic protein (BMP) 8B is a non-invasive predictive biomarker for the diagnosis of non-alcoholic steatohepatitis (NASH).
    PLoS One. 2023;18:e0295839.
    >> Share

    January 2021
  139. YEN HH, Su PY, Huang SP, Wu L, et al
    Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
    PLoS One. 2021;16:e0252286.
    >> Share

  140. CONGLY SE, Shaheen AA, Swain MG
    Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting.
    PLoS One. 2021;16:e0251741.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016